+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review

Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bristol-Myers Squibb Co (BMS) is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes, and commercializes biopharmaceutical products. The company offers its products in therapy areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. It also engages in co-development, co-commercialization, licensing, or joint venture arrangements with third parties to develop specific drugs. BMS distributes its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies through brands such as Opdivo, Reblozyl, Krazati, Sprycel, and Sotyktu, among others. It operates manufacturing units in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands. BMS is headquartered in Princeton, New Jersey, the US.

Bristol-Myers Squibb Co Key Recent Developments

  • May 15, 2026: Tempus broadens collaboration with BMS for clinical trials
  • May 12, 2026: BMS and Hengrui forge $15.2bn alliance for early-stage drugs
  • May 11, 2026: BMS’ Sotyktu secures EC approval for psoriatic arthritis
  • May 01, 2026: BMS brings the buzz around late-stage readouts amid a so-so Q1

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Bristol-Myers Squibb Co - Key Facts
  • Bristol-Myers Squibb Co - Key Employees
  • Bristol-Myers Squibb Co - Key Employee Biographies
  • Bristol-Myers Squibb Co - Major Products and Services
  • Bristol-Myers Squibb Co - History
  • Bristol-Myers Squibb Co - Company Statement
  • Bristol-Myers Squibb Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Bristol-Myers Squibb Co - Business Description
  • Other Break-up: Growth Portfolio
  • Performance
  • Other Break-up: Legacy Portfolio
  • Performance
  • Geographical Segment: International
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Bristol-Myers Squibb Co - Corporate Strategy
  • Bristol-Myers Squibb Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Bristol-Myers Squibb Co - Strengths
  • Bristol-Myers Squibb Co - Weaknesses
  • Bristol-Myers Squibb Co - Opportunities
  • Bristol-Myers Squibb Co - Threats
  • Bristol-Myers Squibb Co - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Bristol-Myers Squibb Co, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 15, 2026: Tempus broadens collaboration with BMS for clinical trials
  • May 12, 2026: BMS and Hengrui forge $15.2bn alliance for early-stage drugs
  • May 11, 2026: BMS’ Sotyktu secures EC approval for psoriatic arthritis
  • May 01, 2026: BMS brings the buzz around late-stage readouts amid a so-so Q1
  • Apr 30, 2026: AI in Clinical Development Summit to Feature Life Sciences and Technology Leaders
  • Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
  • Apr 10, 2026: BMS and Oxford BioTherapeutics join forces in TCE discovery pact
  • Mar 31, 2026: Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
  • Mar 29, 2026: Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results Showing Camzyos Efficacy and Safety in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
  • Mar 29, 2026: Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents With Symptomatic oHCM
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Bristol-Myers Squibb Co, Key Facts
  • Bristol-Myers Squibb Co, Key Employees
  • Bristol-Myers Squibb Co, Key Employee Biographies
  • Bristol-Myers Squibb Co, Major Products and Services
  • Bristol-Myers Squibb Co, History
  • Bristol-Myers Squibb Co, Other Locations
  • Bristol-Myers Squibb Co, Subsidiaries
  • Bristol-Myers Squibb Co, Joint Venture
  • Bristol-Myers Squibb Co, Key Competitors
  • Bristol-Myers Squibb Co, Ratios based on current share price
  • Bristol-Myers Squibb Co, Annual Ratios
  • Bristol-Myers Squibb Co, Interim Ratios
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Bristol-Myers Squibb Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Bristol-Myers Squibb Co, Performance Chart (2021-2025)
  • Bristol-Myers Squibb Co, Ratio Charts
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eli Lilly and Co
  • Abbott Laboratories
  • Theratechnologies Inc
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Checkpoint Therapeutics Inc
  • Viatris Inc
  • Merck & Co Inc
  • Omniox Inc
  • Intercept Pharmaceuticals Inc
  • Allergan Ltd
  • Sangui BioTech International Inc
  • Novartis AG
  • Lescarden Inc
  • Sandoz Inc
  • Sanofi
  • GSK plc